LoQus23 Therapeutics

Cambridge, United Kingdom · Founded 2019 · Privately Held (backing)

Developer of allosteric small molecule inhibitors targeting MSH3/MutSbeta designed to treat Huntington's disease and other triplet repeat neurodegenerative disorders. LoQus23 Therapeutics is based in Cambridge, United Kingdom and was founded in 2019. Its last known valuation is $61.4 million. It has raised $67.2 million.

Last price · $/share
—
Implied valuation
$61.4M
Total raised
$67.2M
Last round
—

Who backs LoQus23 Therapeutics?

3 investors
InvestorType
SV Health InvestorsVenture capital
ForbionVenture capital
Novartis Venture FundOther
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

LoQus23 Therapeutics investors

3 investors are on record for LoQus23 Therapeutics, including SV Health Investors, Forbion and Novartis Venture Fund.

Free account
More of LoQus23 Therapeutics with a free account
  • ·Watch LoQus23 Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 3 firms already write checks for companies like LoQus23 Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View